Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China’s Drug-Buying Growth Attracts Japanese Makers

This article was originally published in PharmAsia News

Executive Summary

China's double-digit growth in pharmaceutical purchases has sparked an interest in Japanese drug makers in expanding their own markets in the country. The Chinese market is soon to surpass Japan to become the world's second-largest, behind only the United States. Astellas Pharma also has scheduled release of one of its drugs for later this year, Eisai is adding representatives and Dainippon Sumitomo Pharma now has a Chinese subsidiary. The Japanese makers see China as a replacement for dwindling markets in the United States and the European Union as the Chinese become more affluent. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts